A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis

Inclusion Criteria: * Subjects with active rheumatoid arthritis as diagnosed by meeting ACR classification criteria for at least 6 months. * Must be taking MTX consecutively for \>/= 12 weeks and at a stable dose of methotrexate at 15-25 mg weekly for at least 4 weeks prior to screening Exclusion Criteria: * Receipt of commercial or experimental biologic therapies for the treatment of inflammatory disease * Presence of serious infection * Class IV rheumatoid arthritis * Prior or current history of tuberculosis infection or exposure * Any other DMARDs other than methotrexate within 6 weeks of screening * Pregnant or nursing * Receipt of live vaccines within 3 months * Felty's syndrome